Investing.com -- Tourmaline Bio, Inc. (NASDAQ: TRML ) stock fell 3% after the company announced positive topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease (CKD). Despite the reported success in the trial, the market response was negative.

The TRANQUILITY trial demonstrated that pacibekitug, an IL-6 inhibitor, provided rapid, deep, and durable reductions in hs-CRP, with high statistical significance over placebo. Moreover, pacibekitug is the first IL-6 inhibitor to show such results with quarterly dosing in a clinical trial. The overall incidence rates of adverse events and serious adverse events were comparable to placebo, suggesting a favorable safety profile.

Tourmaline’s CEO, Sandeep Kulkarni, expressed optimism about the data and the potential for pacibekitug to advance into Phase 3 trials for atherosclerotic cardiovascular disease and a planned Phase 2 trial for abdominal aortic aneurysm. The company plans to share additional data at an upcoming medical conference.

The TRANQUILITY trial, which included participants with elevated hs-CRP and CKD stages 3 or 4, aimed to evaluate the efficacy of pacibekitug in reducing hs-CRP, a biomarker associated with cardiovascular risk. The trial’s primary endpoint was the median time-averaged percent change in hs-CRP through Day 90.

The biotech firm has future plans to advance pacibekitug’s development in cardiovascular inflammation and assess Phase 3 trial designs in patients with atherosclerotic cardiovascular disease. Additionally, a Phase 2 proof-of-concept trial for abdominal aortic aneurysm is expected to commence in the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.